The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine

AIDS

Volumn 20, Issue 14, 2006, Pages 1833-1841

  Aweeka, Francesca T ^a   Rosenkranz, Susan L ^b   Segal, Yoninah ^b   Coombs, Robert W ^c   Bardeguez, Arlene ^d   Thevanayagam, Lourdes ^a,b   Lizak, Patricia ^a   Aberg, Judith ^e   Watts, D Heather ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Contraceptive therapy; Female sex; Intracellular triphosphates; Pharmacokinetics; Zidovudine

Indexed keywords

CONTRACEPTIVE AGENT; RNA; ZIDOVUDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; DRUG THERAPY, COMBINATION; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MEDROXYPROGESTERONE 17-ACETATE; MEDROXYPROGESTERONE ACETATE; MESTRANOL; MIDDLE AGED; NORETHINDRONE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SEX FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 33748513653     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000244202.18629.36     Document Type: Article

References (30)

1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002; 288:222-235.
2. Furman PA, Fyfe JA, St Clair MH, Wienhold K, Rideout JL, Freemna GA, et al. Phopshorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′ triphosphate with human inmmunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986; 83:8333-8337.
3. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990; 249:1533-1544.
4. Anderson PL, Kakuda TN, Kawle S, Fletcher C.Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-2168.
5. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, et al. Zidovudine triphosphate and lamivudine triphosphate concentration response relationships in HIV- infected persons. AIDS 2000; 14:2137-2144.
6. Fletcher CV, Acosta,. Henry K, Page LM, Gross CR, Kawle SP, et al. Concentration controlled zidovudine therapy. Clin Pharmacol Ther 1998; 64:331-338.
7. Stretcher BN, Pesce AJ, Murray JA, Hurtubise PE, Vine WH, Frame PT. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations [abstract]. Ther Drug Monit 1991; 13:325.
8. Becher F, Landman R, Mboup S, Kane CN, Canestri A, Liegeois F, et al. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004; 18:181-187.
9. Becher F, Schlemmer D, Pruvost A, Nevers MC, Goujard C, Jorajuria S, et al. Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells. Anal Chem 2002; 74:4220-4227.
10. Umeh OC, Currier JS. Sex differences in HIV: natural history, pharmacokinetics, and drug toxicity. Curr Infect Dis Rep 2005; 7:73-78.
11. Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24:316-324.
12. Miners JO, Attwood J, Birkett D. Influences of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 1983; 16:503-509.
13. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 1980; 215:86-91.
14. Divoll M, Greenblatt D, Harmatz JS, Shader R. Effect of age and gender on disposition of temazepam. J Pharm Sci 1981; 70:1104-1107.
15. Miners JO, Robson RA, Birkett DJ. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. Br J Clin Pharmacol 1984; 18:240-243.
16. Miners JO, Grgurinovich N, Whitehead A, Robson R, Birkitt D. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br J Clin Pharmacol 1986; 22:135-142.
17. Stoehr G, Kroboth P, Juhi R, Wender D, Phillips J, Smith R. Effect of oral contraceptives on triazolam, temazepam, alprazolam and lorazepam kinetics. Clin Pharmacol Ther 1984; 36:683-690.
18. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb Mort Wkly Rep 1998; 47(RR-5): 1-82. Updated 7 April 2005. Available at http://aidsinfo.nih. gov/guidelines/.
19. Mostad SB, Overbaugh J, DeVange DM, Welch MJ, Chohan B, Mandaliya K, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-927.
20. Thevanayagam LN, Jayewardene AL, Gambertoglio JG. The stability of intracellular zidovudine and its anabolites in extracts of peripheral blood mononuclear cells (PBMCs). J Pharm Biomed Anal 2000; 22:597-603.
21. Coombs RW, Wright DJ, Reichelderfer PS, Burns DN, Cohn J, Cu-Uvin S, et al. Women's Health Study 001 Team. Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women. J Infect Dis 2001; 184:1187-1191.
22. Toernevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S. Cytotoxicity of 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-HIV activity correlates with AZTTP levels in cultured CEMT-lymphoblastoid cells. Biochem Pharmacol 1995; 49:829-837.
23. Bridges EG, Faraj A, Sommadossi JP. Inhibition of mammalian DNA polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine amnd 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1993; 45:1571-1576.
24. Barry M, Wild M, Veal G, Back D, Breckenridge A, Fox R, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8:F1-F5.
25. Arenas-Pinto A, Grant AD, Edwards S, Weller IVD. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003; 79:340-343.
26. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agen Chemother 1994; 38:1541-1547.
27. Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet 1989; 17:1-9.
28. Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 2004; 18:205-209.
29. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17:455-480.
30. Ghanem KG, Shah N, Klein RS, Mayer KH, Sobel JD, Warren DL, et al. for the HIV Epidemiology Research Study Group. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis 2005; 191:358-366.